XML 55 R38.htm IDEA: XBRL DOCUMENT v3.24.0.1
Note 2 - Revenue Recognition - Disaggregation of Revenue By Product and Geography (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Revenue $ 233,662 $ 2,785 $ 6,689
Product [Member]      
Revenue 92,005 2,633 6,537
Briumvi Ublituximab [Member]      
Revenue 92,000    
UNITED STATES | Product [Member]      
Revenue 88,786 2,633 6,537
UNITED STATES | Briumvi Ublituximab [Member] | Product [Member]      
Revenue 88,786    
UNITED STATES | Ukoniq [Member] | Product [Member]      
Revenue   2,633 6,537
International [Member] | Product [Member]      
Revenue 3,219    
International [Member] | Briumvi Ublituximab [Member] | Product [Member]      
Revenue 3,219    
Worldwide [Member] | Product [Member]      
Revenue 92,005 2,633 6,537
Worldwide [Member] | Briumvi Ublituximab [Member] | Product [Member]      
Revenue $ 92,005    
Worldwide [Member] | Ukoniq [Member] | Product [Member]      
Revenue   $ 2,633 $ 6,537